🏛️ Verified NIH Record • Updated 2026-07-13
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis (NCT04754945)
Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Emory University
🩺 Plain-English Summary (8th-Grade Level)
This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Who can join: Review the eligibility criteria below.
Location: University of California — Orange, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- University of California — Orange, California
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Karmanos Cancer Institute — Detroit, Michigan
- Columbia University — New York, New York
- UT Southwestern — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in AL Amyloidosis
- Ixazomib Maintenance Study in Patients With AL Amyloidosis — Boston, Massachusetts
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis — Boston, Massachusetts
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) — Duarte, California
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) — Scottsdale, Arizona
- A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement — Palo Alto, California
Explore by condition: All AL Amyloidosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.